1. InflaRx will present at two major investor conferences in September 2025. 2. The company aims to attract interest in its anti-inflammatory therapies. 3. Meetings provide key opportunity to engage with potential investors. 4. Vilobelimab, their flagship drug, has shown disease-modifying effects in trials. 5. The events could enhance InflaRx's visibility and investor appeal.
Participation in investor conferences can lead to increased investor interest and stock price appreciation, similar to past events where companies announced innovative products or strategic updates. For instance, previous presentations have often correlated with positive market reactions for biopharma firms.
This article outlines key investor events which can significantly affect stock sentiment and trading volume, boosting IFRX's visibility in the market. The prospect of presenting innovative therapies can strengthen investor confidence and interest in IFRX's financial outlook.
The announcements regarding investor conferences typically influence stock price immediately or within weeks as investors react to new information and updates, reflecting a direct market interest.
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows:
Cantor Global Healthcare Conference 2025
September 3 - 5, 2025 in New York, NY
Fireside chat on September 4th at 9:10 AM ET
InflaRx will also conduct one-on-one investor meetings on September 4th. A link to view the fireside chat live stream and its replay is available here.
H.C. Wainwright 27th Annual Global Investment Conference
September 8 - 10, 2025 in New York, NY
Presentation on September 9th at 3:30 PM ET
InflaRx will also conduct one-on-one investor meetings on September 9th. A link to register for the presentation live stream and its replay is available here.
About InflaRx
InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue," among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, "Risk factors" and "Cautionary statement regarding forward looking statements", in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
